{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:20:11Z","timestamp":1773141611623,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Few recent epidemiological data are available on the risks of chronic kidney disease (CKD), cardiovascular events and infections, in patients with LN, even though these data are crucial for guiding therapeutic decisions. We conducted a cohort study with the aim of evaluating survival without CKD and adverse events in patients with LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with a first flare of biopsy-proven LN between 2001 and 2022 followed-up in the University Hospital of Marseille, France, were included in MassiLUP. Patient survival, survival without CKD stages 3, 4 and 5, without cardiovascular event, without severe infection (hospitalization or zoster) and without cancer were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and sixty-eight patients (82.7% female) were included, mean follow-up was 9.6\u2009\u00b1\u20095.7\u2009years. Most patients had class III or IV (+\/\u2212V) LN. Four patients died (three severe infections and one stroke); 41 (24.4%) patients developed CKD, among whom 19 (11.3%) reached ESKD; 34 (20.2%) patients presented a cardiovascular event, 59 (35.1%) a severe infection and 12 (7.1%) a cancer. Survival rates without CKD were 82.9% and 74.6% at 5 and 10\u2009years; without cardiovascular event were 85.7% and 77.3% at 5 and 10\u2009years; without severe infection were 76.3% and 63.8% at 5 and 10\u2009years; without cancer were 96.3% and 92.9% at 5 and 10\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite free access to treatment and care in France, the long-term prognosis of patients with LN remains burdened both by the risk of CKD, and the risks of cardiovascular and infectious events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf532","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T11:19:52Z","timestamp":1760354392000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term renal outcomes, cardiovascular events and severe infections in patients with lupus nephritis: MassiLUP cohort 2001\u20132022"],"prefix":"10.1093","volume":"65","author":[{"given":"B\u00e9rang\u00e8re","family":"Goupille","sequence":"first","affiliation":[{"name":"AP-HM, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, CHU Conception , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mie","family":"Resseguier","sequence":"additional","affiliation":[{"name":"Aix-Marseille Univ, Laboratoire de Sant\u00e9 Publique, CERESS , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Torrents","sequence":"additional","affiliation":[{"name":"AP-HM, Laboratoire d\u2019Anatomie Pathologique, CHU Timone , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-1300","authenticated-orcid":false,"given":"Stanislas","family":"Bataille","sequence":"additional","affiliation":[{"name":"Clinique Bouchard, Centre Phoc\u00e9en de N\u00e9phrologie , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Beaume","sequence":"additional","affiliation":[{"name":"Hopital d\u2019Instruction des Arm\u00e9es Sainte-Anne, AVODD N\u00e9phrologie , Toulon,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micka\u00ebl","family":"Bobot","sequence":"additional","affiliation":[{"name":"AP-HM, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, CHU Conception , Marseille,","place":["France"]},{"name":"Aix-Marseille Univ, C2VN, INSERM, INRAE , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Brunet","sequence":"additional","affiliation":[{"name":"AP-HM, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, CHU Conception , Marseille,","place":["France"]},{"name":"Aix-Marseille Univ, C2VN, INSERM, INRAE , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[{"name":"AP-HM, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, CHU Conception , Marseille,","place":["France"]},{"name":"Aix-Marseille Univ, C2VN, INSERM, INRAE , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Corthier","sequence":"additional","affiliation":[{"name":"CH Avignon, Service de N\u00e9phrologie , Avignon,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Faraut","sequence":"additional","affiliation":[{"name":"AP-HM, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, CHU Conception , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Sallee","sequence":"additional","affiliation":[{"name":"AP-HM, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, CHU Conception , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0582-694X","authenticated-orcid":false,"given":"Laurent","family":"Chiche","sequence":"additional","affiliation":[{"name":"H\u00f4pital Europ\u00e9en, Service de M\u00e9decine interne , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Daniel","sequence":"additional","affiliation":[{"name":"AP-HM, Laboratoire d\u2019Anatomie Pathologique, CHU Timone , Marseille,","place":["France"]},{"name":"Aix-Marseille Univ, C2VN, INSERM, INRAE , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9315-1577","authenticated-orcid":false,"given":"No\u00e9mie","family":"Jourde-Chiche","sequence":"additional","affiliation":[{"name":"AP-HM, Centre de N\u00e9phrologie et Transplantation R\u00e9nale, CHU Conception , Marseille,","place":["France"]},{"name":"Aix-Marseille Univ, C2VN, INSERM, INRAE , Marseille,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2026030916380960400_keaf532-B1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0961203320932219","article-title":"Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression","volume":"29","author":"Mahajan","year":"2020","journal-title":"Lupus"},{"key":"2026030916380960400_keaf532-B2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/0961203313492576","article-title":"Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years","volume":"22","author":"Moroni","year":"2013","journal-title":"Lupus"},{"key":"2026030916380960400_keaf532-B3","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.38731","article-title":"Mortality associated with systemic lupus erythematosus in france assessed by multiple-cause-of-death analysis","volume":"66","author":"Thomas","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026030916380960400_keaf532-B4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/0961203319847275","article-title":"Assessing the relative impact of lupus nephritis on mortality in a population-based systemic lupus erythematosus cohort","volume":"28","author":"Reppe Moe","year":"2019","journal-title":"Lupus"},{"key":"2026030916380960400_keaf532-B5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology"},{"key":"2026030916380960400_keaf532-B6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026030916380960400_keaf532-B7","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.3390\/jcm11175017","article-title":"Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort","volume":"11","author":"Kapsia","year":"2022","journal-title":"J Clin Med"},{"key":"2026030916380960400_keaf532-B8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2026030916380960400_keaf532-B9","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026030916380960400_keaf532-B10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"2026030916380960400_keaf532-B11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"2026030916380960400_keaf532-B12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026030916380960400_keaf532-B13","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.20364","article-title":"Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis","volume":"50","author":"Mok","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026030916380960400_keaf532-B14","doi-asserted-by":"crossref","first-page":"e14427","DOI":"10.1111\/nep.14427","article-title":"Lupus nephritis and chronic kidney disease: a scoping review","volume":"30","author":"Teoh","year":"2025","journal-title":"Nephrology (Carlton)"},{"key":"2026030916380960400_keaf532-B15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/096120339500400206","article-title":"Prognostic determinants in lupus nephritis: a long-term clinicopathologic study","volume":"4","author":"Donadio","year":"1995","journal-title":"Lupus"},{"key":"2026030916380960400_keaf532-B16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/ndt\/gfab152","article-title":"Long-term renal survival of paediatric patients with lupus nephritis","volume":"37","author":"Demir","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026030916380960400_keaf532-B17","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/kead519","article-title":"Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999\u20132022","volume":"63","author":"Moe","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026030916380960400_keaf532-B18","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.3390\/jcm11164860","article-title":"Good long-term prognosis of lupus nephritis in the high-income Afro-Caribbean population of Martinique with free access to healthcare","volume":"11","author":"Suzon","year":"2022","journal-title":"J Clin Med"},{"key":"2026030916380960400_keaf532-B19","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.3390\/jcm12216935","article-title":"Immunosuppressive agents-effects on the cardiovascular system and selected metabolic aspects: a review","volume":"12","author":"Opa\u0142ka","year":"2023","journal-title":"J Clin Med"},{"key":"2026030916380960400_keaf532-B20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/joim.13557","article-title":"Systemic lupus erythematosus and cardiovascular disease","volume":"293","author":"Frosteg\u00e5rd","year":"2023","journal-title":"J Intern Med"},{"key":"2026030916380960400_keaf532-B21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2026030916380960400_keaf532-B22","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2026030916380960400_keaf532-B23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"2026030916380960400_keaf532-B24","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026030916380960400_keaf532-B25","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026030916380960400_keaf532-B26","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/ki.1996.528","article-title":"\u201cNephritic flares\u201d are predictors of bad long-term renal outcome in lupus nephritis","volume":"50","author":"Moroni","year":"1996","journal-title":"Kidney Int"},{"key":"2026030916380960400_keaf532-B27","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1177\/0961203315593166","article-title":"Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis","volume":"24","author":"Yang","year":"2015","journal-title":"Lupus"},{"key":"2026030916380960400_keaf532-B28","doi-asserted-by":"crossref","first-page":"1081942","DOI":"10.3389\/fimmu.2022.1081942","article-title":"Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026030916380960400_keaf532-B29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026030916380960400_keaf532-B30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/art.40724","article-title":"Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes","volume":"71","author":"Mackay","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026030916380960400_keaf532-B31","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis Cohort","volume":"67","author":"Dall\u2019Era","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026030916380960400_keaf532-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.revmed.2022.11.002","article-title":"Lupus nephritis: is it necessary to systematically repeat kidney biopsy?","volume":"44","author":"Bobot","year":"2023","journal-title":"Rev Med Interne"},{"key":"2026030916380960400_keaf532-B33","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/ndt\/gfg345","article-title":"Prognosis in proliferative lupus nephritis: the role of socio-economic status and race\/ethnicity","volume":"18","author":"Barr","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2026030916380960400_keaf532-B34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/BOR.0000000000001030","article-title":"SGLT-2 inhibitors: new horizons for rheumatologists","volume":"36","author":"Chakrabarti","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"2026030916380960400_keaf532-B35","doi-asserted-by":"crossref","first-page":"152746","DOI":"10.1016\/j.semarthrit.2025.152746","article-title":"Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: a national cohort study","volume":"73","author":"Sagy","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026030916380960400_keaf532-B36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026030916380960400_keaf532-B37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf532\/64659151\/keaf532.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf532\/64659151\/keaf532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf532\/64659151\/keaf532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:38:16Z","timestamp":1773088696000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf532\/8284835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf532","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,13]]},"article-number":"keaf532"}}